What they do: Pharmaceutical Preparations · Exchange: Nasdaq · Employees: 29
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania. (via Yahoo Finance)
| Quarter end | Revenue | Diluted EPS |
|---|
Insiders hold: 11.60% · Institutions hold: 103.84% across 277 filers
| Institution | Shares | Value | % held |
|---|---|---|---|
| Montanova Capital LLC | 1,135,406 | $144.6M | 7.88% |
| Jennison Associates LLC | 960,619 | $122.3M | 6.67% |
| Blackrock Inc. | 918,357 | $116.9M | 6.37% |
| Frazier Life Sciences Management, L.P. | 882,400 | $112.4M | 6.12% |
| First Light Asset Management, LLC | 771,901 | $98.3M | 5.36% |
| BVF Inc. | 672,789 | $85.7M | 4.67% |
| State Street Corporation | 653,172 | $83.2M | 4.53% |
| Price (T.Rowe) Associates Inc | 638,868 | $81.4M | 4.43% |
| Trade date | Filed | Name | Role | Action | Shares | Price | Value | Stock since |
|---|---|---|---|---|---|---|---|---|
| 2026-10-14 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 476 | $121.14 | $58K | +3.9% |
| 2026-10-14 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 505 | $126.55 | $64K | +3.9% |
| 2026-10-14 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 597 | $125.33 | $75K | +3.9% |
| 2026-10-14 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 920 | $124.37 | $114K | +3.9% |
| 2026-10-14 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 2,072 | $122.62 | $254K | +3.9% |
| 2026-10-14 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 2,604 | $123.29 | $321K | +3.9% |
| 2026-10-13 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 579 | $132.40 | $77K | -0.9% |
| 2026-10-13 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 922 | $133.72 | $123K | -0.9% |
| 2026-10-13 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 990 | $130.48 | $129K | -0.9% |
| 2026-10-13 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 1,035 | $131.49 | $136K | -0.9% |
| 2026-10-13 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 1,644 | $129.23 | $212K | -0.9% |
| 2026-10-13 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 2,004 | $128.52 | $258K | -0.9% |
| 2026-10-12 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 817 | $136.44 | $111K | -5.2% |
| 2026-10-12 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 1,447 | $135.50 | $196K | -5.2% |
| 2026-10-12 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 2,458 | $133.25 | $328K | -5.2% |
| 2026-10-12 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 3,335 | $134.21 | $448K | -5.2% |
| 2026-10-12 | 2026-10-14 | JENKINS GEORGE M | Director | SOLD | 5,095 | $132.62 | $676K | -5.2% |